640 related articles for article (PubMed ID: 20890241)
1. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
Qian J; Lu Q; Tao Y; Jiang YR
Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
[TBL] [Abstract][Full Text] [Related]
2. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
3. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy.
Hattori T; Shimada H; Nakashizuka H; Mizutani Y; Mori R; Yuzawa M
Retina; 2010 May; 30(5):761-4. PubMed ID: 20453802
[TBL] [Abstract][Full Text] [Related]
4. Apelin in epiretinal fibrovascular membranes of patients with retinopathy of prematurity and the changes after intravitreal bevacizumab.
Zhang Y; Jiang YR; Lu Q; Yin H; Tao Y
Retina; 2013 Mar; 33(3):613-20. PubMed ID: 23296045
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
Ma Y; Zhang Y; Zhao T; Jiang YR
Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
[TBL] [Abstract][Full Text] [Related]
6. Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab.
Kubota T; Morita H; Tou N; Nitta N; Tawara A; Satoh H; Shimajiri S
Retina; 2010 Mar; 30(3):468-72. PubMed ID: 19952991
[TBL] [Abstract][Full Text] [Related]
7. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T
Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy.
Sawada O; Kawamura H; Kakinoki M; Sawada T; Ohji M
Arch Ophthalmol; 2007 Oct; 125(10):1363-6. PubMed ID: 17923544
[TBL] [Abstract][Full Text] [Related]
9. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity.
Sato T; Kusaka S; Shimojo H; Fujikado T
Ophthalmology; 2009 Sep; 116(9):1599-603. PubMed ID: 19371954
[TBL] [Abstract][Full Text] [Related]
10. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.
Matsuyama K; Ogata N; Matsuoka M; Wada M; Nishimura T; Takahashi K
J Ocul Pharmacol Ther; 2011 Aug; 27(4):379-83. PubMed ID: 21810018
[TBL] [Abstract][Full Text] [Related]
11. Apelin in plasma and vitreous and in fibrovascular retinal membranes of patients with proliferative diabetic retinopathy.
Tao Y; Lu Q; Jiang YR; Qian J; Wang JY; Gao L; Jonas JB
Invest Ophthalmol Vis Sci; 2010 Aug; 51(8):4237-42. PubMed ID: 20220056
[TBL] [Abstract][Full Text] [Related]
12. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.
Oshima Y; Shima C; Wakabayashi T; Kusaka S; Shiraga F; Ohji M; Tano Y
Ophthalmology; 2009 May; 116(5):927-38. PubMed ID: 19269033
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial.
Ahmadieh H; Shoeibi N; Entezari M; Monshizadeh R
Ophthalmology; 2009 Oct; 116(10):1943-8. PubMed ID: 19699531
[TBL] [Abstract][Full Text] [Related]
14. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy.
Liu L; Wu WC; Yeung L; Wang NK; Kuo YH; Chao AN; Chen KJ; Chen TL; Lai CC; Hwang YS; Chen YP
Ophthalmic Surg Lasers Imaging; 2010; 41(1):72-7. PubMed ID: 20128573
[TBL] [Abstract][Full Text] [Related]
15. Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy.
Suzuki Y; Suzuki K; Yokoi Y; Miyagawa Y; Metoki T; Nakazawa M
Retina; 2014 Jan; 34(1):165-71. PubMed ID: 23851630
[TBL] [Abstract][Full Text] [Related]
16. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
Watanabe D; Suzuma K; Suzuma I; Ohashi H; Ojima T; Kurimoto M; Murakami T; Kimura T; Takagi H
Am J Ophthalmol; 2005 Mar; 139(3):476-81. PubMed ID: 15767056
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic shift in vitreous after vitrectomy in patients with proliferative diabetic retinopathy.
Yoshida S; Nakama T; Ishikawa K; Arima M; Tachibana T; Nakao S; Sassa Y; Yasuda M; Enaida H; Oshima Y; Kono T; Ishibashi T
Invest Ophthalmol Vis Sci; 2012 Oct; 53(11):6997-7003. PubMed ID: 22977138
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy.
Cancarini A; Costagliola C; Dell'omo R; Romano M; Morescalchi F; Agnifili L; Ruggeri G; Semeraro F
Minerva Endocrinol; 2014 Dec; 39(4):305-11. PubMed ID: 25371057
[TBL] [Abstract][Full Text] [Related]
19. Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications.
El-Sabagh HA; Abdelghaffar W; Labib AM; Mateo C; Hashem TM; Al-Tamimi DM; Selim AA
Ophthalmology; 2011 Apr; 118(4):636-41. PubMed ID: 21055812
[TBL] [Abstract][Full Text] [Related]
20. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]